세계의 폐동맥 고혈압(PAH) 치료 시장 : 약제 클래스별, 투여 경로별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모 및 점유율, 예측(2024-2032년)

REPORT HIGHLIGHT

The Pulmonary Arterial Hypertension (PAH) Treatment Market was valued at USD 7,980.43 million in 2023 and expanded at a CAGR of 5.90% from 2024 to 2032.

Pulmonary Arterial Hypertension (PAH) is an uncommon yet significant medical condition marked by increased blood pressure within the pulmonary arteries, potentially resulting in heart failure and various other complications. The primary objective of PAH treatment is to alleviate symptoms, enhance the quality of life, and decelerate the progression of the disease. Consistent monitoring of symptoms, functional capacity, and the effectiveness of treatment are essential for the successful management of PAH. Typically, a multidisciplinary team of healthcare professionals, including cardiologists, pulmonologists, and pulmonary medicine specialists, collaborates to provide thorough management of the condition.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Market Dynamics

Increasing Prevalence of Pulmonary Arterial Hypertension (PAH) is anticipated to drive the growth of the market

As the global demographic shifts towards an older population, the prevalence of pulmonary arterial hypertension (PAH) is anticipated to increase, especially among elderly individuals who are more vulnerable to chronic health issues. The rising number of patients with chronic diseases who subsequently develop PAH will likely necessitate comprehensive management approaches, thereby heightening the demand for various treatment alternatives. PAH is classified as a rare condition, with prevalence estimates ranging from 10 to 52 cases per million individuals. According to the European Respiratory Society, PAH (Group 1 pulmonary hypertension) is further divided based on the underlying disease mechanisms. Nevertheless, enhanced investment in clinical research may facilitate the emergence of novel therapies, thereby broadening the market. Conversely, limited awareness among healthcare professionals could hinder market expansion.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.90% over the forecast period (2024-2032)

Based on Drug Class segmentation, Endothelin Receptor Antagonists (ERA) was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading Drug Class in 2023

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading Drug Class in 2023

Based on region, North America was the leading revenue generator in 2023

Pulmonary Arterial Hypertension (PAH) Treatment Market- Segmentation Analysis:

The Global Pulmonary Arterial Hypertension (PAH) Treatment Market is segmented based on Drug Class, Route of Administration, Distribution Channel, and Region.

The market is categorized into four segments according to Drug Class: Prostacyclin and Prostacyclin Analogs, Phosphodiesterase 5 (PDE 5) Inhibitors, Endothelin Receptor Antagonists (ERA), and Soluble Guanylate Cyclase (SGC) Stimulators. Among these, Endothelin Receptor Antagonists (ERAs) holds a dominant position in the market. ERAs are essential in the treatment of pulmonary arterial hypertension (PAH) as they inhibit the effects of endothelin, a vasoconstrictor that contributes to elevated blood pressure in the pulmonary arteries associated with PAH.

The market is segmented into three categories according to the Route of Administration: Oral, Intravenous/Subcutaneous, and Inhalational. The Oral category is the primary driver of market growth. Oral therapies are especially significant for pulmonary arterial hypertension (PAH) as they provide convenience in administration, are generally appropriate for long-term use, and enhance patient adherence, particularly for individuals needing continuous management of this chronic illness.

The market is segmented into three categories according to the Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies hold a dominant position in the market. They function as the principal distribution channel for PAH medications, particularly for therapies that necessitate close medical oversight, including intravenous and injectable treatments.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Geographical Insights

The North American region leads the market, attributed to its advanced healthcare infrastructure and specialized medical facilities. Healthcare providers in North America benefit from access to state-of-the-art diagnostic and therapeutic technologies, which enhance disease management and lead to better patient outcomes. According to the American Medical Association, health expenditures in the United States rose by 4.1% in 2022, reaching USD 4.5 trillion, or USD 13,493 per capita. This growth rate aligns with pre-pandemic figures, which also stood at 4.1% in 2019. Meanwhile, the Asia-Pacific region offers significant growth potential, driven by a strong focus on research and development. As awareness and diagnostic capabilities continue to advance, the PAH treatment market is expected to experience sustained growth across multiple regions.

Pulmonary Arterial Hypertension (PAH) Treatment Market- Competitive Landscape:

The market for Pulmonary Arterial Hypertension (PAH) treatment is characterized by intense competition, with a multitude of pharmaceutical firms dedicated to creating groundbreaking therapies for this chronic and potentially fatal condition. A prevalent strategy among these companies is the ongoing investment in clinical trials aimed at evaluating new therapies, combinations, and dosage forms, as such advancements may redefine the standards of care for PAH. Additionally, many organizations are broadening their operations in emerging markets, where there is an increasing awareness and diagnosis of PAH, to gain a competitive advantage.

Recent Developments:

A novel formulation of treprostinil, known as Yutrepia, may soon be accessible to individuals suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), following the tentative approval granted by the Food and Drug Administration (FDA) earlier this month.

Pfizer Inc. has announced that a Phase 3 clinical trial aimed at evaluating the efficacy and safety of intravenous (IV) sildenafil in conjunction with inhaled nitric oxide (iNO) for treating newborns with Persistent Pulmonary Hypertension (PPHN) did not achieve its primary efficacy objective.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• United Therapeutics Ltd.
• Bayer AG
• Actelion Ltd.
• Pfizer, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Teva Pharmaceuticals Inc.
• Eli Lilly and Company
• Steady Med Ltd.
• Johnson & Johnson Services, Inc.
• Others

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

• Prostacyclin and Prostacyclin Analogs
• Phosphodiesterase 5 (PDE 5) Inhibitors
• Endothelin Receptor Antagonists (ERA)
• Soluble Guanylate Cyclase (SGC) Stimulator

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

• Oral
• Intravenous/ subcutaneous
• Inhalational

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Pulmonary Arterial Hypertension (PAH) Treatment Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Drug Class
  • 2.1.2. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Route of Administration
  • 2.1.3. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Distribution Channel
  • 2.1.4. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Country
  • 2.1.5. Pulmonary Arterial Hypertension (PAH) Treatment Market Snippet by Region
• 2.2. Competitive Insights

3. Pulmonary Arterial Hypertension (PAH) Treatment Key Market Trends

• 3.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Pulmonary Arterial Hypertension (PAH) Treatment Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Pulmonary Arterial Hypertension (PAH) Treatment Market Opportunities
• 3.4. Pulmonary Arterial Hypertension (PAH) Treatment Market Future Trends

4. Pulmonary Arterial Hypertension (PAH) Treatment Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Pulmonary Arterial Hypertension (PAH) Treatment Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Pulmonary Arterial Hypertension (PAH) Treatment Market Landscape

• 6.1. Pulmonary Arterial Hypertension (PAH) Treatment Market Share Analysis, 2023
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Drug Class

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
  • 7.1.2. Prostacyclin and Prostacyclin Analogs
  • 7.1.3. Phosphodiesterase 5 (PDE 5) Inhibitors
  • 7.1.4. Endothelin Receptor Antagonists (ERA)
  • 7.1.5. Soluble Guanylate Cyclase (SGC) Stimulator

8. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Route of Administration

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
  • 8.1.2. Oral
  • 8.1.3. Intravenous/ subcutaneous
  • 8.1.4. Inhalational

9. Pulmonary Arterial Hypertension (PAH) Treatment Market - By Distribution Channel

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
  • 9.1.2. Hospital Pharmacies
  • 9.1.3. Retail Pharmacies
  • 9.1.4. Online Pharmacies

10. Pulmonary Arterial Hypertension (PAH) Treatment Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Pulmonary Arterial Hypertension (PAH) Treatment Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Pulmonary Arterial Hypertension (PAH) Treatment Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. United Therapeutics Ltd.
  • 11.2.2. Bayer AG
  • 11.2.3. Actelion Ltd.
  • 11.2.4. Pfizer, Inc.
  • 11.2.5. Gilead Sciences, Inc.
  • 11.2.6. GlaxoSmithKline plc
  • 11.2.7. Teva Pharmaceuticals Inc.
  • 11.2.8. Eli Lilly and Company
  • 11.2.9. Steady Med Ltd.
  • 11.2.10. Johnson & Johnson Services, Inc.
  • 11.2.11. Others

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us